Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.37% | -126.55% | -46.04% | -79.64% | -114.66% |
| Total Depreciation and Amortization | -42.86% | 24.36% | -14.66% | -10.81% | 24.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 183.96% | 263.43% | 173.15% | 71.18% | 124.85% |
| Change in Net Operating Assets | 233.25% | 3,057.82% | 9.85% | 956.06% | 40.97% |
| Cash from Operations | -4.44% | -71.20% | -43.67% | -64.45% | -84.93% |
| Capital Expenditure | 58.33% | -345.16% | 80.00% | -170.59% | 25.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,004.06% | 261.80% | 22.39% | 2,133.64% | 370.65% |
| Cash from Investing | -1,005.59% | 260.98% | 22.40% | 2,162.19% | 368.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 459,995.03% | -87.21% | 92,698.99% | 1,108.51% | -99.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 459,160.87% | -87.69% | 92,640.88% | 125.87% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,648.96% | 54.98% | 115.23% | 120.06% | -106.42% |